185 related articles for article (PubMed ID: 36621846)
21. Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia.
Zhou H; Xu RZ; Gu Y; Shi PF; Qian S
Leuk Lymphoma; 2020 May; 61(5):1084-1096. PubMed ID: 29334312
[TBL] [Abstract][Full Text] [Related]
22. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Homoharringtonine for the Treatment of Acute Myeloid Leukemia: A Meta-analysis.
Mi R; Zhao J; Chen L; Wei X; Liu J; Wei X
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e752-e767. PubMed ID: 34301487
[TBL] [Abstract][Full Text] [Related]
24. Identification of long non-coding RNA MVIH as a prognostic marker and therapeutic target in acute myeloid leukemia.
Jiang Z; Yu Q; Luo X
J Clin Lab Anal; 2020 Apr; 34(4):e23113. PubMed ID: 31724217
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic Value of
LE N; Yang JJ; Liu YC; Zhang XW; Wang H; Wen YN; Jiao YF; Wang LL; Dou LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):355-364. PubMed ID: 38660836
[TBL] [Abstract][Full Text] [Related]
26. The prognostic value of RASGEF1A RNA expression and DNA methylation in cytogenetically normal acute myeloid leukemia.
He X; Zhang W; Fu W; Liu X; Yang P; Wang J; Zhu M; Li S; Zhang W; Zhang X; Dong G; Yan C; Zhao Y; Zeng Z; Jing H
Cancer Biomark; 2023; 36(2):103-116. PubMed ID: 36404533
[TBL] [Abstract][Full Text] [Related]
27. ZEB1 serves as an oncogene in acute myeloid leukaemia via regulating the PTEN/PI3K/AKT signalling pathway by combining with P53.
Li L; Feng Y; Hu S; Du Y; Xu X; Zhang M; Peng X; Chen F
J Cell Mol Med; 2021 Jun; 25(11):5295-5304. PubMed ID: 33960640
[TBL] [Abstract][Full Text] [Related]
28.
Bai H; Zhou M; Zeng M; Han L
DNA Cell Biol; 2020 Apr; 39(4):700-708. PubMed ID: 32077754
[TBL] [Abstract][Full Text] [Related]
29. Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC.
Li C; Dong L; Su R; Bi Y; Qing Y; Deng X; Zhou Y; Hu C; Yu M; Huang H; Jiang X; Li X; He X; Zou D; Shen C; Han L; Sun M; Skibbe J; Ferchen K; Qin X; Weng H; Huang H; Song C; Chen J; Jin J
Haematologica; 2020 Jan; 105(1):148-160. PubMed ID: 30975912
[TBL] [Abstract][Full Text] [Related]
30. Pivotal role of DPYSL2A in KLF4-mediated monocytic differentiation of acute myeloid leukemia cells.
Noura M; Morita K; Kiyose H; Matsuo H; Nishinaka-Arai Y; Kurokawa M; Kamikubo Y; Adachi S
Sci Rep; 2020 Nov; 10(1):20245. PubMed ID: 33219287
[TBL] [Abstract][Full Text] [Related]
31. High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects.
Li X; Li C; Jin J; Wang J; Huang J; Ma Z; Huang X; He X; Zhou Y; Xu Y; Yu M; Huang S; Yan X; Li F; Pan J; Wang Y; Yu Y; Jin J
EBioMedicine; 2018 Dec; 38():47-56. PubMed ID: 30472087
[TBL] [Abstract][Full Text] [Related]
32. [Cytotoxicity of homoharringtonine on leukemic stem-like cells in AML cell line KG-1].
Shen JP; Yang H; Ni WM; Qian WB
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):485-90. PubMed ID: 23086639
[TBL] [Abstract][Full Text] [Related]
33. Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single-arm, phase 2 trial (RJ-AML 2014).
Zhang Y; Li X; Weng X; Shen Y; Chen Y; Zheng Y; Zhao H; You J; Mao Y; Wang L; Wu M; Sheng Y; Wu J; Hu J; Chen Q; Li J
Am J Hematol; 2022 Jan; 97(1):43-51. PubMed ID: 34687467
[TBL] [Abstract][Full Text] [Related]
34. Loss of IRF8 inhibits the growth of acute myeloid leukemia cells.
Zhuang H; Li F; Xu Y; Pei R; Chen D; Liu X; Li S; Ye P; Yuan J; Lian J; Lu Y
Ann Hematol; 2023 May; 102(5):1063-1072. PubMed ID: 36959484
[TBL] [Abstract][Full Text] [Related]
35. The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia.
Li X; Yin X; Wang H; Huang J; Yu M; Ma Z; Li C; Zhou Y; Yan X; Huang S; Jin J
Oncotarget; 2017 Feb; 8(8):12764-12774. PubMed ID: 28061447
[TBL] [Abstract][Full Text] [Related]
36. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
[TBL] [Abstract][Full Text] [Related]
37. [Synergistic effect of azacitidine with homoharringtonine by activating the c-MYC/DDIT3/PUMA axis in acute myeloid leukemia].
Li J; Huang YQ; Zi J; Song CH; Ge Z
Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1001-1009. PubMed ID: 38503523
[No Abstract] [Full Text] [Related]
38. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.
Metzeler KH; Heilmeier B; Edmaier KE; Rawat VP; Dufour A; Döhner K; Feuring-Buske M; Braess J; Spiekermann K; Büchner T; Sauerland MC; Döhner H; Hiddemann W; Bohlander SK; Schlenk RF; Bullinger L; Buske C
Blood; 2012 Sep; 120(10):2118-26. PubMed ID: 22815426
[TBL] [Abstract][Full Text] [Related]
39. Synergistic Lethality Effects of Apatinib and Homoharringtonine in Acute Myeloid Leukemia.
Shi Y; Xu D; Xu Y; Shen H; Zhang Y; Ye X; Jin J; Cui D; Xie W
J Oncol; 2022; 2022():9005804. PubMed ID: 36081666
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA‑93 knockdown inhibits acute myeloid leukemia cell growth via inactivating the PI3K/AKT pathway by upregulating DAB2.
Huang J; Xiao R; Wang X; Khadka B; Fang Z; Yu M; Zhang L; Wu J; Liu J
Int J Oncol; 2021 Oct; 59(4):. PubMed ID: 34476495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
